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Our research focuses on the molecular design and synthesis of specific inhibitors of physiologically important 
enzymes (biocatalysts). The enzyme inhibitors are used for probing the reaction mechanisms, three-dimensional 
structures and identifying the physiological roles of the enzymes. The finely designed inhibitors are further elaborated to 
develop useful bioactive substances that could knockout the specific enzyme in vivo to develop lead compounds for 
novel pharmaceuticals, agrochemicals and cosmetic ingredients. Our current research includes the design, synthesis and 
applications of transition-state analogue and/or mechanism-based inhibitors of such enzymes as γ-glutamyl 
transpeptidase, a key enzyme in glutathione metabolism, asparagine synthetase, an important enzyme for cancer 
chemotherapy, and 4-coumaroyl CoA ligase that plays 
a pivotal role in the biosynthesis of a vast array of 
phenylpropanoid in plants. The identification of the 
genes of hitherto unknown enzymes for biosynthesis of 
phenylpropanoid volatiles in plants are also pursued to 
shed light on the detailed reaction mechanisms and the 
physiological function of the biosynthetic enzymes in 
plant secondary metabolites.
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Development and Applications of Specific 
Inhibitors of g-Glutamyl Transpeptidase, a Key 
Enzyme in Glutathione Metabolism
Glutathione (GSH, γ-Glu-Cys-Gly) is a ubiquitous 
 redox active tripeptide containing Cys and plays central 
roles in detoxification of reactive oxygen species (ROS) 
and toxic xenobiotics in the front line of cellular defense 
system. γ-Glutamyltranspeptidase (GGT) is a key enzyme 
in GSH metabolism that catalyzes the cleavage of 
γ-glutamyl peptide bond of extracellular GSH to supply 
cells with Cys, a rate-limiting substrate for intracellular 
GSH biosynthesis. Hence GGT is implicated in many 
physiological disorders such as drug resistance of cancer 
cells, cardiovascular diseases and asthma. We have devel-
oped a phosphonate-based mechanism-based inhibitor, 
GGsTopTM, that was a highly specific and non-toxic inhib-
itor of GGT. A series of phosphonate-based GGT inhibi-
tors with a peptidyl side chain have also been synthesized 
for evaluation as inhibitors of human and E. coli GGTs to 
probe the Cys-Gly binding site (Figure 1).
Interestingly, GGsTopTM, a highly efficient inhibitor of 
human GGT, induces cellular anti-oxidative stress response. 
As a result, this compound exhibited interesting biological 
activities such as increasing the biosynthesis of type I 
 collagen, elastin and HSP47 of human dermal fibroblasts 
(Figure 2). These properties, along with its non-toxic nature, 
allowed GGsTopTM to serve as a novel active ingredient 
for anti-ageing cosmetics. This compound are now mar-
keted under a trade name of “Nahlsgen®” and has attracted 
significant interests from the cosmetic market.
Inhibitors Targeting Human Asparagine 
Synthetase for Cancer Chemotherapy
A standard current clinical protocol for acute lym-
phoblastic leukemia (ALL) is the use of the enzyme l-
asparagine amidohydrolase (ASNase) that catalyzes the 
hydrolysis of l-Asn to deplete circulating l-Asn in blood. 
The efficacy of ASNase chemotherapy, however, is ham-
pered by the emergence of ASNase-resistant leukemic 
blasts; 10–12% of patients who initially go into remission 
undergo subsequent relapse . One widely-accepted hypoth-
esis for ASNase resistance is the up-regulation of gluta-
mine- and ATP-dependent asparagine synthetase (ASNS) 
that enables the leukemia cells to synthesize l-Asn neces-
sary for their growth. Hence the inhibition of human 
ASNS is highly important in cancer chemotherapy, and 
we have synthesized a specific inhibitor of human ASNS. 
According to the proposed reaction mechanism of ASNS 
in which the β-carboxy group of l-Asp is activated by ad-
enylation followed by nucleophilic substitution by ammo-
nia to yield l-Asn, AMP and PPi, an N-adenylated sulfoxi-
mine 1 was synthesized as a transition-state analogue 
inhibitor of ASNS (Figure 3).
Compound 1 was found to be an extremely potent 
inhibitor of human ASNS; it inhibited the enzyme in a 
time-dependent manner with an overall Ki* of 8 nM. 
Furthermore, the inhibitor 1 suppressed cell proliferation 
of ASNase-resistant MOLT-4R leukemia cells (Figure 4) 
with an IC50 of ca. 0.1 mM. Surprisingly, compound 1 
 induced cell death as well as suppression of cell prolifera-
tion at higher concentrations. ASNase-sensitive leuke-
mia cells with low ASNS activity were much less 
sensitive toward compound 1, suggesting that ASNS in it-
self was an essential enzyme for leukemia cells and was 
an important drug target for cancer chemotherapy.
Figure 3. Reaction mechanism of asparagine synthetase and its transition-
state analogue 1.
Figure 1. Mechanism-based inhibition of GGT by GGsTopTM and pepti-
dyl phosphonate inhibitors 1a-g.
Figure 2. Mechanism for activation of human fibroblasts by GGT in-
hibitor, GGsTopTM.
Figure 4. The effect of ASNS inhibitor 1 on the proliferation of ASNase-
resistant MOLT-4 leukemia cells in the presence and absence of 1U 
asparaginase . (Left) MOLT-4 cells with ASNase; (right) MOLT-4R cells 
without ASNase. Cell proliferation is defined as the number of viable 
cells after 48 h incubation.
